drugset
drugset / Trial / NCT05718882

Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

NCT05718882 ↗

Terminated 5 enrolled RenJi Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with Aurora kinase A inhibitor VIC-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).

Timeline

Start
2023-08-30
Primary completion
2024-04-02
Completion
2024-04-02

Outcome

Outcome not reported

Stopped: “The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg, 150 mg, 200 mg BID) was scientifically unjustified, lacking prior clinical safety data to support such starting doses when combined with lenvatinib in HC”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject VIC-1911 Unknown 50 mg Oral
Subject VIC-1911 Unknown 100 mg Oral
Subject VIC-1911 Unknown 150 mg Oral
Subject VIC-1911 Unknown 200 mg Oral
Subject VIC-1911 Unknown 250 mg Oral

Indications

hepatocellular carcinoma refractory malignant neoplasm